These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 15057512

  • 1. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B.
    Intensive Care Med; 2004 May; 30(5):976-9. PubMed ID: 15057512
    [Abstract] [Full Text] [Related]

  • 2. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B.
    Intensive Care Med; 2004 May; 30(5):989-91. PubMed ID: 14985960
    [Abstract] [Full Text] [Related]

  • 3. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia.
    Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B.
    Crit Care Med; 2003 Aug; 31(8):2102-6. PubMed ID: 12973166
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
    Alvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, Maraví-Poma E, Torres-Martí A, Nava J, Martínez-Pellús A, Palomar M, Barcenilla F, Spanish Collaborative Group for the Study of Severe Infections.
    Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.
    Boselli E, Breilh D, Rimmelé T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B.
    Crit Care Med; 2005 Jul; 33(7):1529-33. PubMed ID: 16003058
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
    Réa-Neto A, Niederman M, Lobo SM, Schroeder E, Lee M, Kaniga K, Ketter N, Prokocimer P, Friedland I.
    Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
    [Abstract] [Full Text] [Related]

  • 7. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [Abstract] [Full Text] [Related]

  • 8. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
    Lü Y, Yan Z, Wang DH, Dong WL, Yang Y, Xia R.
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
    [Abstract] [Full Text] [Related]

  • 9. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B.
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 12. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
    Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P, Moutschen M.
    J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H, Lv Y, Wang D, Xue J, Yan Z.
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [Abstract] [Full Text] [Related]

  • 14. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM, Cheatham SC, Smith DW, Wack MF, Sowinski KM, Kays MB.
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [Abstract] [Full Text] [Related]

  • 15. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
    Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, Chiolero R, Ricou B, Romand J, Huber O, Ambrosetti P, Praz G, Lew D, Bille J, Glauser MP, Cometta A.
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
    [Abstract] [Full Text] [Related]

  • 16. Pulmonary penetration of piperacillin and tazobactam in critically ill patients.
    Felton TW, McCalman K, Malagon I, Isalska B, Whalley S, Goodwin J, Bentley AM, Hope WW.
    Clin Pharmacol Ther; 2014 Oct; 96(4):438-48. PubMed ID: 24926779
    [Abstract] [Full Text] [Related]

  • 17. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [Abstract] [Full Text] [Related]

  • 18. Antibiotic therapy of ventilator-associated pneumonia: in search of the magic bullet.
    Brun-Buisson C.
    Chest; 2003 Mar; 123(3):670-3. PubMed ID: 12628858
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
    Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.